Update to ASCO metastatic pancreatic cancer guidelines

  • Sohal DPS & al.
  • J Clin Oncol
  • 20 Aug 2018

  • curated by Jim Kling
  • Univadis Clinical Summaries
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • The update incorporates changes based on a randomized controlled trial of olaparib vs placebo, phase 1 and 2 studies of larotrectinib, and phase 1 and 2 studies of entrectinib.

Why this matters

  • The guideline focuses advice on appropriate therapy after disease progression or intolerable toxicity.

Key updates

  • Patients likely to be candidates for post-first-line treatments should be tested during their initial assessment for actionable germline and somatic genomic alterations, including microsatellite instability/mismatch repair deficiency, BRCA mutations, and NTRK gene fusions.
  • First-line therapy: Nab-paclitaxel or capecitabine or erlotinib can be added to gemcitabine for patients with either an Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 2 or a comorbidity profile that precludes more aggressive regimens, but who wish to receive cancer treatment.
    • Proactive dose and schedule adjustments should be made to minimize toxicity.
  • In patients with BRCA1/2 germline mutations who undergo first-line platinum-based chemotherapy and have no disease progression for a minimum of 16 weeks, continued treatment options include chemotherapy or olaparib.
  • Second-line:
    • Patients with NTRK fusion-containing tumors should be treated with larotrectinib or entrectinib.
    • Among patients who have undergone first-line treatment with a gemcitabine-based regimen, have an ECOG PS of 0-1, a favorable comorbidity profile, and a support system for aggressive medical therapy and can get a chemotherapy port and infusion pump management services, fluorouracil plus nanoliposomal irinotecan, or fluorouracil plus irinotecan if the former is not available, is preferred.
    • For patients with ECOG PS 2 or unfavorable comorbidity profile for aggressive regimens, gemcitabine or fluorouracil can be used.
      • Nab-paclitaxel can be added to gemcitabine or nanoliposomal irinotecan to fluorouracil, with proactive dose and schedule adjustments to minimize toxicity.